156 related articles for article (PubMed ID: 34430621)
1. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy.
Xing X; Zhou X; Yang Y; Li Y; Hu C; Shen C
Ann Transl Med; 2021 Jul; 9(14):1180. PubMed ID: 34430621
[TBL] [Abstract][Full Text] [Related]
2. A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
Liu T; Sun Q; Chen J; Wang F; Li B; Qin W; Ye Z; Hu F
Cancer Manag Res; 2018; 10():6237-6245. PubMed ID: 30538570
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
4. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
5. Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W; Chuner J; Lei W; Fengqin Y; Zhimin Y; Quanquan S; Tongxin L; Min X; Peng W; Bin L; Aizawa R; Sakamoto M; Zhenfu F
Oncotarget; 2017 Oct; 8(53):91150-91161. PubMed ID: 29207632
[TBL] [Abstract][Full Text] [Related]
6. Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Du C; Ying H; Zhou J; Hu C; Zhang Y
Int J Clin Oncol; 2013 Jun; 18(3):464-71. PubMed ID: 22527846
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy.
Hung CJ; Kang BH; Chang KM; Kang YY; Yin CH; Lee CC
BMC Cancer; 2022 Oct; 22(1):1084. PubMed ID: 36271346
[TBL] [Abstract][Full Text] [Related]
8. Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer.
Halvorsen TO; Valan CD; Slaaen M; Grønberg BH
J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1283-1290. PubMed ID: 32725772
[TBL] [Abstract][Full Text] [Related]
9. Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis.
Zhang J; Peng H; Chen L; Li WF; Mao YP; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
J Cancer; 2017; 8(13):2587-2594. PubMed ID: 28900496
[No Abstract] [Full Text] [Related]
10. Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma.
Guo L; Lin HX; Xu M; Chen QY; Wang CT; Huang PY
Chin J Cancer; 2010 Feb; 29(2):136-9. PubMed ID: 20109339
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Yuan TZ; Zheng RH
J Cancer; 2021; 12(1):18-27. PubMed ID: 33391399
[No Abstract] [Full Text] [Related]
12. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study.
Huang X; Lv LN; Zhao Y; Li L; Zhu XD
Clin Nutr; 2021 Jan; 40(1):295-302. PubMed ID: 32507513
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
Liao JF; Zhang Q; Du XJ; Lan M; Liu S; Xia YF; Cai XY; Luo W
Cancer Commun (Lond); 2019 Jun; 39(1):40. PubMed ID: 31248459
[TBL] [Abstract][Full Text] [Related]
14. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
Rimar KJ; Glaser AP; Kundu S; Schaeffer EM; Meeks J; Psutka SP
Bladder Cancer; 2018 Oct; 4(4):411-418. PubMed ID: 30417052
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
[TBL] [Abstract][Full Text] [Related]
17. Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Yang J; Han J; He J; Duan B; Gou Q; Ai P; Liu L; Li Y; Ren K; Wang F; Yao M; Chen N
Front Oncol; 2020; 10():594756. PubMed ID: 33425747
[TBL] [Abstract][Full Text] [Related]
18. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
19. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
Zhang L; Shan GP; Li P; Cheng PJ
Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
Yao JJ; Yu XL; Zhang F; Zhang WJ; Zhou GQ; Tang LL; Mao YP; Chen L; Ma J; Sun Y
Chin J Cancer; 2017 Mar; 36(1):26. PubMed ID: 28264724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
